Nanobiotix revenues for the 3rd quarter of 2017
November 15 2017 - 1:07PM
Business Wire
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN: FR0011341205), a
late clinical-stage nanomedicine company pioneering new approaches
to the treatment of cancer, today announces its unaudited revenues
for the third quarter of 2017.
Income Statement for the third quarter of 2017
In € Q3 2017 Q2 2017
Q1 2017 Q3 2016 Revenues
33,018 58,645 -
58,556
Of which :LicenseServices
-33,018
14658,499
--
46,35112,205
Year-to-date income statement as of September 30th,
2017
In €
09/30/2017
(9 months)
09/30/2016
(9 months)
Revenues 91,663 1,040,723
Of which :LicenseServices
14691,517
1,028,51812,205
Activity and results
In total, revenue for the third quarter amounted to €33,018.
This brings the revenue for the first nine months of 2017 to
€91,663, which is fully in line with the Company’s
expectations.
Most of the revenues generated by the Company during this period
come from services that Nanobiotix crossed-charged to its partners
as per its operational activities.
In September, Nanobiotix announced its intention to start its
first clinical trial with NBTXR3 in combination with immune
checkpoint inhibitors in the U.S., with a multi-arm trial targeting
a sub-population of advanced lung, and head and neck cancer
patients. The medium-term objective is to transform non-responders
into checkpoint inhibitor responders while improving patients’
benefits. The trial aims to evaluate the ability of NBTXR3 to
generate an abscopal effect.
This trial also aims to expand the potential for NBTXR3,
including using it to treat recurrent or metastatic disease. The
trial would begin by combining NBTXR3 with any approved checkpoint
inhibitors in head and neck squamous cell carcinoma or non-small
cell lung cancer.
-Ends-
Next financial press release: revenue for Q4 2017 by February
28, 2018
About NANOBIOTIX: www.nanobiotix.com
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late
clinical-stage nanomedicine company pioneering novel approaches for
the treatment of cancer. The Company’s first-in-class, proprietary
technology, NanoXray, enhances radiotherapy energy with a view to
providing a new, more efficient treatment for cancer patients.
NanoXray products are compatible with current radiotherapy
treatments and are meant to treat potentially a wide variety of
solid tumors including soft tissue sarcoma, head and neck cancers,
liver cancers, prostate cancer, breast cancer, glioblastoma, etc.,
via multiple routes of administration.
NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head
and neck cancers, prostate cancer, and liver cancers (primary and
metastases). Additionally, head and neck cancer and rectal cancer
trials led by Nanobiotix’s Taiwanese partner, PharmaEngine, are
underway in the Asia Pacific region. The Company filed in August
2016 for market approval (CE Marking) in Europe for its lead
product NBTXR3.
In 2016 the Company started a new preclinical research program
in Immuno-oncology with its lead product NBTXR3, which could have
the potential to bring a new dimension to cancer
immunotherapies.
Nanobiotix is listed on the regulated market of Euronext in
Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO:
FP). The Company’s Headquarters is based in Paris, France, with a
U.S. affiliate in Cambridge, MA.
Disclaimer
This press release contains certain forward-looking statements
concerning Nanobiotix and its business. Such forward-looking
statements are based on assumptions that Nanobiotix considers to be
reasonable. However, there can be no assurance that the estimates
contained in such forward-looking statements will be verified,
which estimates are subject to numerous risks including the risks
set forth in the reference document of Nanobiotix filed with the
French Financial Markets Authority (Autorité des Marchés
Financiers) under number D.17-0470 on April 28, 2017 (a copy of
which is available on www.nanobiotix.com) and to the development of
economic conditions, financial markets and the markets in which
Nanobiotix operates. The forward-looking statements contained in
this press release are also subject to risks not yet known to
Nanobiotix or not currently considered material by Nanobiotix. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Nanobiotix to
be materially different from such forward-looking statements.
This press release and the information that it contains do not
constitute an offer to sell or subscribe for, or a solicitation of
an offer to purchase or subscribe for, Nanobiotix shares in any
country. At the moment NBTXR3 does not bear a CE mark and is not
permitted to be placed on the market or put into service until
NBTXR3 has obtained a CE mark.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171115006229/en/
NanobiotixSarah Gaubert, +33 (0)1 40 26 07 55Director,
Communications & Public Affairssarah.gaubert@nanobiotix.com /
contact@nanobiotix.comorNoël Kurdi, +1-646-241-4400Director,
Investor Relationsnoel.kurdi@nanobiotix.com /
investors@nanobiotix.comorMedia relationsFrance - Springbok
ConsultantsMarina Rosoff, +33 (0)6 71 58 00
34marina@springbok.frorUnited States –
RooneyPartnersMarion Janic,
+1-212-223-4017mjanic@rooneyco.com
Nanometrics (NASDAQ:NANO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nanometrics (NASDAQ:NANO)
Historical Stock Chart
From Apr 2023 to Apr 2024